News | Heart Failure | January 10, 2017

First-in-the-World Study Looks to Repair Heart Damage

Minneapolis Heart Institute Foundation to conduct first-ever study combining different types of stem cells to repair heart damage for those with ischemic heart failure

ischemic heart failure, stem cell therapy, MSCs, CSCs, Minneapolis Heart Institute Foundation, MHIF study

January 10, 2017 — Ischemic heart failure from previous heart attacks and coronary artery disease is the leading cause of death in the world, affecting more than 12 percent of the world’s population, according to the World Health Organization. Stem cell therapy has been conducted to try to repair heart damage from ischemic heart failure, but in previous studies, the two types of stem cells (autologous bone marrow derived mesenchymal  cells [MSCs] and endomyocardial biopsy derived c-kit+ Cardiac Stem Cells [CSCs]) have been used in separate trials. In a first-in-the-world study, the Minneapolis Heart Institute Foundation (MHIF) is about to begin the CONCERT study, led by Principal Investigator Jay Traverse, M.D. The study will use MSCs and CSCs together to learn if the combination would be more successful than using either alone based on pre-clinical studies in swine demonstrating an enhanced synergistic effect of the combination.

This study is sponsored by the National Institutes of Health and the Cardiovascular Cell Therapy Research Network (CCTRN), of which MHIF is a charter member. The focus of the study is to assess the relative safety of CSCs and MSCs, delivered alone or in combination, when compared to placebo. Researchers will analyze any change or improvement in left ventricular (LV) function by cardiac magnetic resonance imaging (MRI) as well as clinical outcomes and quality of life.

The study is a phase II, randomized, blinded, placebo-controlled study of 160 subjects at the seven CCTRN sites throughout the United States. All recruited subjects will have an ischemic cardiomyopathy with an ejection fraction < 35 percent and must have a significant amount of scar tissue as measured by the MRI (> 5 percent). The first 16 patients were recently enrolled in a U.S. Food and Drug Administration (FDA)-required safety run-in phase, with the remaining patients to be enrolled in the fall after a three-month safety analysis is performed. This will be the first cardiac stem cell trial to perform MRIs on patients with defibrillators and pacemakers

“This combination of cells represents the most potent cell therapy product ever delivered to patients,” said Traverse. “Confirming that both types of stem cells together work better than either individual cell type could lead to improved patient outcomes and better quality of life for ischemic heart failure patients.”

For more information: www.mplsheart.org

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init